Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
A Dietary Intervention- Randomized Controlled Trial (DIRECT) Study; BGU-Harvard–Robarts Collaboration
This study is ongoing, but not recruiting participants.
Sponsors and Collaborators: The S. Daniel Abraham International Center for Health and Nutrition
Harvard School of Public Health
Robarts Research Institute
Soroka University Medical Center
Brigham and Women's Hospital
Harvard University
The Nuclear Research Center, Dimona
Ben-Gurion University of the Negev
Information provided by: The S. Daniel Abraham International Center for Health and Nutrition
ClinicalTrials.gov Identifier: NCT00160108
  Purpose

Aim-to conduct a randomized clinical intervention study to compare three diets (low-fat, low-carbohydrate and Mediterranean diet) for weight loss


Condition Intervention Phase
Obesity
CHD
Behavioral: dietary intervention
Phase I

MedlinePlus related topics: Obesity Weight Control
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Further study details as provided by The S. Daniel Abraham International Center for Health and Nutrition:

Primary Outcome Measures:
  • weight loss

Secondary Outcome Measures:
  • CVD mediators measurements

Estimated Enrollment: 300
Study Start Date: July 2005
Estimated Study Completion Date: July 2007
Detailed Description:

Aim-to conduct a randomized clinical intervention study to compare three diets (low-fat, low-carbohydrate and Mediterranean diet) for weight loss

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • BMI>27
  • age>40
  • History of CHD or diabetes in any age or BMI level

Exclusion Criteria:

  • Pregnant or lactating women.
  • Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
  • Serum creatinine > 3 mg/dl.
  • Liver dysfunction ( ³ 2 fold level of ALT and AST enzymes).
  • Participation in another trial in which active intervention is being received.
  • Any intestinal problem that would prevent the patient from eating one of the test diets (for example, gastric stapling that might prevent consumption of vegetables).
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00160108

Locations
Israel
Medical Center, The Nuclear Research Center
Dimona, Israel, 70700
Sponsors and Collaborators
The S. Daniel Abraham International Center for Health and Nutrition
Harvard School of Public Health
Robarts Research Institute
Soroka University Medical Center
Brigham and Women's Hospital
Harvard University
The Nuclear Research Center, Dimona
Ben-Gurion University of the Negev
Investigators
Principal Investigator: Iris Shai, RD, PhD Ben-Gurion University of the Negev
Study Chair: Meir J Stampfer, MD, DrPH Departments of Epidemiology and Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA
Study Chair: David Spence, MD Stroke Prevention & Atherosclerosis Research Centre, Robarts Research Institute, London, Canada
  More Information

Publications:
Publications indexed to this study:
Study ID Numbers: DR300-3
Study First Received: September 8, 2005
Last Updated: September 11, 2006
ClinicalTrials.gov Identifier: NCT00160108  
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Study placed in the following topic categories:
Body Weight
Signs and Symptoms
Obesity
Nutrition Disorders
Overweight
Overnutrition

ClinicalTrials.gov processed this record on January 16, 2009